According to CoinMeta, Jiuzhitang announced that the Phase IIb clinical trial of its holding subsidiary, Jiuzhitang Meike (Beijing) Cell Technology Co., Ltd.'s human bone marrow mesenchymal stem cell injection for the treatment of autoimmune alveolar proteinosis, held a kick-off meeting on November 13, 2026. This drug is registered as a Class 1 new medicine and is independently developed and produced by Beijing Meike. Previously, this indication had already received implied permission for clinical trials. The clinical trials were initiated in November 2023, and the recruitment of participants was completed. After reaching the main trial endpoints in March 2026, an analysis report was submitted. Following evaluation by the National Medical Products Administration, it was agreed to proceed with the Phase III clinical trials.